NR3C2 and hypertensive disorder: In a double-blind, randomized, phase III study of 1001 Japanese patients with essential hypertension (the ESAX-HTN study), esaxerenone 2.5 mg/day was demonstrated to have antihypertensive activity at least equivalent to that of the MR blocker eplerenone at a dosage of 50 mg/day, and was generally well tolerated [12].